Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 20/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | STK16 | O75716 | 1/20 | 0.35 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.35 |
| ▸ | LATS1 | O95835 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | FER | P16591 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | ERCC2 | P18074 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29783098 | 1.00 | PTK2 (0.40) | PTK2AURKAJAK2STK16CDKL5 | |
| Hydrochloric Acid SCHEMBL29051685 | 0.98 | PTK2 (0.39) | PTK2AURKAJAK2STK16CDKL5 | |
| Acetic Acid SCHEMBL1625936 | 0.92 | PTK2 (0.39) | PTK2AURKAJAK2STK16CDKL5 | |
| Acetic Acid SCHEMBL29853564 | 0.92 | PTK2 (0.39) | PTK2AURKAJAK2STK16CDKL5 | |
| SCHEMBL23087025 | 0.88 | PTK2 (0.33) | PTK2 | |
| SCHEMBL28427090 | 0.88 | PTK2 (0.33) | PTK2 | |
| SCHEMBL29133918 | 0.82 | PTK2 (0.39) | PTK2AURKAJAK2STK16CDKL5 | |
| SCHEMBL29051675 | 0.82 | PTK2 (0.39) | PTK2AURKAJAK2STK16CDKL5 | |
| SCHEMBL17258895 | 0.79 | JAK2 (0.33) | JAK2TYK2JAK3 | |
| SCHEMBL14479713 | 0.79 | PTK2 (0.45) | PTK2AURKAJAK2STK16CDKL5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214967-A1 | FAK DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BERRYBIO SHANGHAI LTD (CN) | 2025-07-03 | — | — | US | disclosed |
| US-20250127800-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | SIGNET THERAPEUTICS INC. (CN) | 2025-04-24 | — | — | US | disclosed |
| EP-4450493-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | Signet Therapeutics Inc. (CN) | 2024-10-23 | — | — | EP | disclosed |
| EP-3792257-B1 | DEUTERATED DEFACTINIB COMPOUND AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20240059678-A1 | Synthesis Method for Aminopyrimidine FAK Inhibitor Compound | HINOVA PHARMACEUTICALS INC. (CN) | 2024-02-22 | — | — | US | disclosed |
| US-11891379-B2 | Deuterated Defactinib compound and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2024-02-06 | — | — | US | disclosed |
| EP-4279488-A1 | SYNTHESIS METHOD FOR AMINOPYRIMIDINE FAK INHIBITOR COMPOUND | Hinova Pharmaceuticals Inc. (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-4279488-A1 | SYNTHESIS METHOD FOR AMINOPYRIMIDINE FAK INHIBITOR COMPOUND | Hinova Pharmaceuticals Inc. (CN) | 2023-11-22 | — | — | EP | disclosed |
| CN-117043151-A | Pyrimidine or pyridine derivative and medical application thereof | 希格生科（深圳）有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-117043163-A | Pyrrolopyrimidine or pyrrolopyridine derivative and medical application thereof | 希格生科（深圳）有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20150080368-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8440822-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. | 2013-05-14 | — | — | US | disclosed |
| US-20130005964-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER, INC. | 2013-01-03 | — | — | US | disclosed |
| US-20130005964-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER, INC. | 2013-01-03 | — | — | US | disclosed |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2011-07-07 | — | — | US | disclosed |
| US-7928109-B2 | focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928109-B2 | focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2009-02-26 | — | — | US | disclosed |
| WO-2008129380-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059678-A1 | Synthesis Method for Aminopyrimidine FAK Inhibitor Compound | PTK2, PARP16, CDK6 | PTK2 1/4885AURKA 609/4885JAK2 53/4885 |
| US-20150080368-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885AURKA 1617/4885JAK2 990/4885 |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885AURKA 1617/4885JAK2 990/4885 |
| US-20130005964-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885AURKA 1617/4885JAK2 990/4885 |
| US-20250214967-A1 | FAK DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | PTK2, CTTN, SRC | PTK2 1/4885AURKA 2234/4885JAK2 142/4885 |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885AURKA 1617/4885JAK2 990/4885 |
| US-11891379-B2 | Deuterated Defactinib compound and use thereof | ARHGDIB, KRAS, CTTN | PTK2 5/4885AURKA 2877/4885JAK2 309/4885 |
| US-20250127800-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | PTK2, PDGFRB, PTK2B | PTK2 1/4885AURKA 510/4885JAK2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.